Dapagliflozin and Exenatide to Improve Health Conditions in Patients Suffering from Type 2 Diabetes

Release Date: 13-Nov-2020

Researchers have tested a drug combination called as dapagliflozin and exenatide in the treatment of the patients suffering from type 2 diabetes. Although there are several different drugs that are used for the treatment of type 2 diabetes but each and every drug available is acting for short time. Therefore, researchers are more inclined towards developing a drug therapy that can act in long-term. As per researchers, it has been found that their drug combination of dapagliflozin and exenatide can control the level of glucose in the patients for more than 2 years which is much more than the other therapies available.


Total 695 patients having type 2 diabetes were enrolled in the study. The patients were divided into 3 groups. 1st group received weekly exenatide injections with metformin. 2nd group received dapagliflozin pills in addition to metformin and the third group received combination of both the drugs. Dapagliflozin is a Na-Glu co-transporter 2 inhibitor which is estimated to excretion of glucose in the urine. Whereas exenatide is a glucagon-like peptide-1 receptor agonists which is believed to stimulate glucose-dependent insulin secretion, lower hepatic glucose output, slow gastric emptying, and increase satiety. The combination of both the drugs is estimated to maintain the level of glucose and cause weight loss and improvement in the blood pressure.

It was found after the clinical trial, that the group of patients who received both the drugs were having stable disease level which was observed for 2 years. Also, the combination of the drugs resulted in weight loss, blood pressure ad improvement in overall health of the patients. It is estimated that such clinical outcomes received from both the drugs made the researchers feel confident about taking the study into further clinical research sector.

Need custom market research solution? We can help you with that too.